• In February 2026, Neogen Corporation announced a voluntary recall of all in-date lots of its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution after microbial contamination was detected and adverse events were reported in horses, and the company is working with the FDA while its investigation continues.
• Management has emphasized that no adverse events have been linked to use strictly following the labeled directions, highlighting how product handling and administration practices may be central to understanding the recall’s root cause and future risk controls.
• We’ll now examine how this voluntary recall of HYCOAT® for contamination concerns could influence Neogen’s broader investment narrative and longer-term business outlook.

Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

Neogen Investment Narrative Recap

To own Neogen today, you have to believe that tightening global food and animal safety standards will keep demand for its testing and health products resilient, even as the company works through integration issues and persistent losses. The HYCOAT recall adds a fresh, product specific quality and regulatory risk on the Animal Safety side, but based on what is known so far, it does not obviously change the near term focus on fixing 3M Food Safety integration and margin pressure.

The most relevant recent development alongside the recall is Neogen’s updated FY2026 guidance in January, when management raised revenue expectations to US$845 million to US$855 million despite ongoing losses. That guidance, issued before the HYCOAT issue emerged, underpins the current catalyst of operational improvement and gradual recovery, and the recall now sits as a potential swing factor around whether those revenue and margin ambitions prove achievable.

Yet behind that improved guidance, investors should be aware of the risk that ongoing operational missteps or product quality issues could...

Neogen's narrative projects $859.1 million revenue and $107.3 million earnings by 2028. This requires a 1.3% yearly revenue decline and an earnings increase of about $1.2 billion from -$1.1 billion today.

Uncover how Neogen's forecasts yield a $8.17 fair value, a 28% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming roughly US$855.4 million of revenue by 2028 and still unappealing profitability, and the HYCOAT recall may reinforce their concerns about operational and regulatory execution.

Explore 3 other fair value estimates on Neogen - why the stock might be worth 28% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Neogen research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.

No Opportunity In Neogen?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.